• Maze Therapeutics targets MZE829 pivotal trial initiation in the first half of 2027, subject to regulatory feedback.
• Phase 2 HORIZON enrollment is complete with more than 50 patients; data from all three cohorts are expected in early 2027.
• Initial results showed a 36% mean reduction in urine albumin-to-creatinine ratio across 12 evaluable patients; no serious adverse events were reported.
• MZE782's phenylketonuria trial is enrolling, with topline data expected in 2027; a chronic kidney disease trial is planned for the first half.
• Expected cash runway extends into 2029 based on the current business plan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.